Literature DB >> 12084931

Urokinase-urokinase receptor interaction mediates an inhibitory signal for HIV-1 replication.

Massimo Alfano1, Nicolai Sidenius, Barbara Panzeri, Francesco Blasi, Guido Poli.   

Abstract

Elevated levels of soluble urokinase-type plasminogen activator (uPA) receptor, CD87/u-PAR, predict survival in individuals infected with HIV-1. Here, we report that pro-uPA (or uPA) inhibits HIV-1 expression in U937-derived chronically infected promonocytic U1 cells stimulated with phorbol 12-myristate 13-acetate (PMA) or tumor necrosis factor-alpha (TNF-alpha). However, pro-uPA did not inhibit PMA or TNF-alpha-dependent activation of nuclear factor-kB or activation protein-1 in U1 cells. Cell-associated HIV protein synthesis also was not decreased by pro-uPA, although the release of virion-associated reverse transcriptase activity was substantially inhibited, suggesting a functional analogy between pro-uPA and the antiviral effects of IFNs. Indeed, cell disruption reversed the inhibitory effect of pro-uPA on activated U1 cells, and ultrastructural analysis confirmed that virions were preferentially retained within cell vacuoles in pro-uPA treated cells. Neither expression of endogenous IFNs nor activation of the IFN-inducible Janus kinase/signal transducer and activator of transcription pathway were induced by pro-uPA. Pro-uPA also inhibited acute HIV replication in monocyte-derived macrophages and activated peripheral blood mononuclear cells, although with great inter-donor variability. However, pro-uPA inhibited HIV replication in acutely infected promonocytic U937 cells and in ex vivo cultures of lymphoid tissue infected in vitro. Because these effects occurred at concentrations substantially lower than those affecting thrombolysis, pro-uPA may represent a previously uncharacterized class of antiviral agents mimicking IFNs in their inhibitory effects on HIV expression and replication.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12084931      PMCID: PMC124389          DOI: 10.1073/pnas.142078099

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  64 in total

1.  Membrane raft microdomains mediate lateral assemblies required for HIV-1 infection.

Authors:  S Mañes; G del Real; R A Lacalle; P Lucas; C Gómez-Moutón; S Sánchez-Palomino; R Delgado; J Alcamí; E Mira; C Martínez-A
Journal:  EMBO Rep       Date:  2000-08       Impact factor: 8.807

Review 2.  Exploitation of cellular signaling by HIV-1: unwelcome guests with master keys that signal their entry.

Authors:  W Popik; P M Pitha
Journal:  Virology       Date:  2000-10-10       Impact factor: 3.616

3.  HIV-1 actively replicates in naive CD4(+) T cells residing within human lymphoid tissues.

Authors:  D A Eckstein; M L Penn; Y D Korin; D D Scripture-Adams; J A Zack; J F Kreisberg; M Roederer; M P Sherman; P S Chin; M A Goldsmith
Journal:  Immunity       Date:  2001-10       Impact factor: 31.745

4.  Amino-terminal fragment of urokinase-type plasminogen activator inhibits HIV-1 replication.

Authors:  M Wada; N A Wada; H Shirono; K Taniguchi; H Tsuchie; J Koga
Journal:  Biochem Biophys Res Commun       Date:  2001-06-08       Impact factor: 3.575

5.  Nonproliferating bystander CD4+ T cells lacking activation markers support HIV replication during immune activation.

Authors:  D Scales; H Ni; F Shaheen; J Capodici; G Cannon; D Weissman
Journal:  J Immunol       Date:  2001-05-15       Impact factor: 5.422

6.  Eotaxin promotes eosinophil transmigration via the activation of the plasminogen-plasmin system.

Authors:  C Ferland; M Guilbert; F Davoine; N Flamand; J Chakir; M Laviolette
Journal:  J Leukoc Biol       Date:  2001-05       Impact factor: 4.962

7.  The binding subunit of pertussis toxin inhibits HIV replication in human macrophages and virus expression in chronically infected promonocytic U1 cells.

Authors:  M Alfano; G Vallanti; P Biswas; C Bovolenta; E Vicenzi; B Mantelli; T Pushkarsky; R Rappuoli; A Lazzarin; M Bukrinsky; G Poli
Journal:  J Immunol       Date:  2001-02-01       Impact factor: 5.422

8.  Urokinase receptors promote beta1 integrin function through interactions with integrin alpha3beta1.

Authors:  Y Wei; J A Eble; Z Wang; J A Kreidberg; H A Chapman
Journal:  Mol Biol Cell       Date:  2001-10       Impact factor: 4.138

9.  Multimerization of human immunodeficiency virus type 1 Gag promotes its localization to barges, raft-like membrane microdomains.

Authors:  O W Lindwasser; M D Resh
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

10.  Urokinase plasminogen activator and plasmin efficiently convert hemofiltrate CC chemokine 1 into its active.

Authors:  J Vakili; L Ständker; M Detheux; G Vassart; W G Forssmann; M Parmentier
Journal:  J Immunol       Date:  2001-09-15       Impact factor: 5.422

View more
  14 in total

1.  Induction of a Soluble Anti-HIV-1 factor (s) with IFN-γ, IL-10, and β-Chemokine Modulating Activity by an Influenza-Bacterial Polyantigenic Mixture.

Authors:  José W Rodríguez; Nat O Pagan; María C Ocasio; Zilka Ríos; Luis A Cubano; Nawal M Boukli; Miguel Otero; Robert Hunter; Madhavan P Nair; Eddy Rios-Olivares
Journal:  Am J Infect Dis       Date:  2007

Review 2.  Host hindrance to HIV-1 replication in monocytes and macrophages.

Authors:  Anna Bergamaschi; Gianfranco Pancino
Journal:  Retrovirology       Date:  2010-04-07       Impact factor: 4.602

3.  Extracellular ATP induces the rapid release of HIV-1 from virus containing compartments of human macrophages.

Authors:  Francesca Graziano; Marion Desdouits; Livia Garzetti; Paola Podini; Massimo Alfano; Anna Rubartelli; Roberto Furlan; Philippe Benaroch; Guido Poli
Journal:  Proc Natl Acad Sci U S A       Date:  2015-06-08       Impact factor: 11.205

4.  Ligand-engaged urokinase-type plasminogen activator receptor and activation of the CD11b/CD18 integrin inhibit late events of HIV expression in monocytic cells.

Authors:  Massimo Alfano; Samanta A Mariani; Chiara Elia; Ruggero Pardi; Francesco Blasi; Guido Poli
Journal:  Blood       Date:  2008-10-21       Impact factor: 22.113

5.  Expression of the urokinase plasminogen activator receptor (uPAR) and its ligand (uPA) in brain tissues of human immunodeficiency virus patients with opportunistic cerebral diseases.

Authors:  Manuela Nebuloni; Paola Cinque; Nicolai Sidenius; Angelita Ferri; Eleonora Lauri; Elisabetta Omodeo-Zorini; Pietro Zerbi; Luca Vago
Journal:  J Neurovirol       Date:  2008-12-24       Impact factor: 2.643

6.  Urokinase plasminogen activator inhibits HIV virion release from macrophage-differentiated chronically infected cells via activation of RhoA and PKCε.

Authors:  Francesca Graziano; Chiara Elia; Carlo Laudanna; Guido Poli; Massimo Alfano
Journal:  PLoS One       Date:  2011-08-17       Impact factor: 3.240

7.  In vitro whole-genome analysis identifies a susceptibility locus for HIV-1.

Authors:  Corinne Loeuillet; Samuel Deutsch; Angela Ciuffi; Daniel Robyr; Patrick Taffé; Miguel Muñoz; Jacques S Beckmann; Stylianos E Antonarakis; Amalio Telenti
Journal:  PLoS Biol       Date:  2008-02       Impact factor: 8.029

8.  The prognostic value of the suPARnostic ELISA in HIV-1 infected individuals is not affected by uPAR promoter polymorphisms.

Authors:  Uffe V Schneider; Rikke L Nielsen; Court Pedersen; Jesper Eugen-Olsen
Journal:  BMC Infect Dis       Date:  2007-11-16       Impact factor: 3.090

9.  uPAR-induced cell adhesion and migration: vitronectin provides the key.

Authors:  Chris D Madsen; Gian Maria Sarra Ferraris; Annapaola Andolfo; Orla Cunningham; Nicolai Sidenius
Journal:  J Cell Biol       Date:  2007-06-04       Impact factor: 10.539

10.  Full-length soluble urokinase plasminogen activator receptor down-modulates nephrin expression in podocytes.

Authors:  Massimo Alfano; Paola Cinque; Guido Giusti; Silvia Proietti; Manuela Nebuloni; Silvio Danese; Silvia D'Alessio; Marco Genua; Federica Portale; Manuela Lo Porto; Pravin C Singhal; Maria Pia Rastaldi; Moin A Saleem; Domenico Mavilio; Joanna Mikulak
Journal:  Sci Rep       Date:  2015-09-18       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.